Lumos Wins Three-Year Manufacturing Deal for Micro-Pak Mold Analyzer

An update from Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) is now available.

Lumos Diagnostics has signed a three-year contract manufacturing agreement with Micro-Pak Ltd. to produce the newly launched Micro-Pak Mold Analyzer system, a rapid on-site mold detection solution for both professional and consumer use. The deal, which follows four years of development collaboration and includes an initial purchase order of US$250,000, underscores Lumos’ ability to convert development projects into recurring manufacturing revenue and strengthens its services business as Micro-Pak scales commercial deployment of the Mold Analyzer across global supply chains.

The Mold Analyzer system integrates a world-first rapid test cassette capable of detecting 56 mold species with Lumos’ proprietary digital camera reader and a custom mobile application. This combination enables faster, traceable mold testing throughout manufacturing and logistics networks, while offering a low-cost stand-alone visual test option for home users and enhancing Micro-Pak’s existing lab-based mold analysis services.

The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.

More about Lumos Diagnostics Holdings Ltd.

Lumos Diagnostics Holdings Ltd. is an Australia-based provider of rapid, point-of-care diagnostic technologies for healthcare and commercial applications. The company develops, manufactures, and commercializes custom assay solutions, digital reader platforms, and its own branded tests targeting infectious and inflammatory diseases, while also offering contract development and manufacturing services.

Average Trading Volume: 4,422,138

Technical Sentiment Signal: Buy

Current Market Cap: A$168.6M

Find detailed analytics on LDX stock on TipRanks’ Stock Analysis page.